Active	Status	Sponsor type	Region	Phase	Filter
5 Active 25 Inactive 30 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Barak, Adiel
NR, NCT04295304: 600 System Retinal Prosthesis for Patients With Retinal Degenerative Diseases	Terminated	N/A	9	Europe, RoW	Retinal surgery with implantation of epi-retinal device	Nano Retina, MedPass International	Retinitis Pigmentosa, Retinal Degeneration	03/23	03/23
Shulman, Shiri
NCT05417152: Single In-Clinic Encounter With the Notal Vision Home OCT by DME Patients	Completed	N/A	18	RoW		Notal Vision Inc.	Diabetic Retinopathy	11/22	03/23
NCT04078672: Retinal Imaging Using NOTAL-OCT V3.0	Completed	N/A	58	RoW	NOTAL-OCT V3.0, OCT scan	Notal Vision Ltd.	AMD, DR	01/23	03/23
NCT05433792: To Evaluate the Effectiveness of New Specially Designed Fitlens Soft Lens.	Recruiting	N/A	66	RoW	Myolens CN (Central-Near) soft contact lens, Myolens CF (Central-Far) soft contact lens, MiSight® soft contact lens	Fitlens Ltd., RSNESS	Myopia	01/26	01/26
Bechor, Sagit
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Nov 2022 - Nov 2022: Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Jun 2022 - Jun 2022: Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 May 2022 - May 2022: Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 More	Recruiting	3	330	Europe, Canada, US, RoW	Selinexor, KPT-330, Placebo, Ruxolitinib	Karyopharm Therapeutics Inc	Myelofibrosis	09/25	03/28
Varssano, David
No trials found
Schwartz, Roy
No trials found
Wilner, Zohar
No trials found
Ohana, Oded
No trials found
Keren, Shay
No trials found
Goldenberg, Dafna
No trials found
Neuderfer, Meira
No trials found
Guzner-Gur, Chanan
No trials found
Nutman, Amir
No trials found